Beryl Drugs (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Beryl Drugs Limited |
|||
|
Price: ₹37.25 | ||
| 52 Week Low: ₹22.09 52 Week High: ₹46.00 |
|||
| Market Capital: 16.38 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Beryl Drugs Share Price Target For 2024
- 1.1.1: Beryl Drugs Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Beryl Drugs Share Price Target For 2025
- 1.2.1: Beryl Drugs Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Beryl Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Beryl Drugs Financial Performance
- 3.0.1: Is Beryl Drugs A Good Buy For Long Term?
To predict the Beryl Drugs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Beryl Drugs Share Price Target For 2024
The line chart displays the monthly closing prices of Beryl Drugs with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Beryl Drugs shares in 2024, see the table below.
Beryl Drugs Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 39.72 (+6.63%) | Price Action: 21 Feb 2024 Low |
| 2024 Target 2 | 39.27 (+5.42%) | Price Action: 05 Mar 2024 High |
| 2024 Target 1 | 38.77 (+4.08%) | Price Action: 16 Dec 2024 High |
| Current Price | 37.25 | Beryl Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 36.59 (-1.78%) | Price Action: 25 Sep 2024 Low |
| Stop Loss 2 | 36.2 (-2.82%) | Price Action: 18 Oct 2024 Low |
| Stop Loss 3 | 35.8 (-3.9%) | Price Action: Jul 2024 High |
Short-Term Technical Outlook
Current Technical Position: Beryl Drugs is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹36.21 serves as the nearest technical reference point.
Historical Returns: 3-month: -1.66% | 6-month: +16.44% | 1-year: +68.48%
Beryl Drugs Share Price Target For 2025
The line chart displays the monthly closing prices of Beryl Drugs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Beryl Drugs shares in 2025, see the table below.
Beryl Drugs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 54.64 (+46.68%) | Price Action: Chart |
| 2025 Target 2 | 53.62 (+43.94%) | Price Action: Chart |
| 2025 Target 1 | 53.09 (+42.52%) | Fibonacci Extension Level 64.90% |
| Current Price | 37.25 | Beryl Drugs's share price as of 26 Dec 2024 |
| Stop Loss 1 | 33.61 (-9.77%) | Price Action: 18 Apr 2024 Low |
| Stop Loss 2 | 33.25 (-10.74%) | Price Action: 23 Oct 2024 Low |
| Stop Loss 3 | 32.9 (-11.68%) | Price Action: 27 Aug 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Beryl Drugs is currently trading at 63.4% of its 52-week range (₹22.09 - ₹46).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +68.48% | 3-year: +207.34% | 5-year: +661.76%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Beryl Drugs Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹37.25 | ||
| 2024 | ₹32.54 | -12.64% | ₹33.51 |
| 2025 | ₹42.88 | +31.77% | ₹43.72 |
| 2026 | ₹49.91 | +16.39% | ₹50.95 |
| 2027 | ₹59.52 | +19.25% | ₹60.41 |
| 2028 | ₹61.21 | +2.83% | ₹62.13 |
| 2029 | ₹61.17 | -0.06% | ₹68.57 |
| 2030 | ₹74.97 | +22.56% | ₹76.85 |
| 2031 | ₹82.39 | +9.89% | ₹85.23 |
| 2032 | ₹93.80 | +13.84% | ₹95.21 |
| 2033 | ₹92.82 | -1.04% | ₹94.21 |
| 2034 | ₹89.81 | -3.24% | ₹99.04 |
| 2035 | ₹107.06 | +19.2% | ₹108.67 |
| 2036 | ₹114.87 | +7.29% | ₹116.59 |
| 2037 | ₹128.08 | +11.49% | ₹130.00 |
| 2038 | ₹124.42 | -2.85% | ₹126.55 |
| 2039 | ₹123.27 | -0.92% | ₹136.65 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Beryl Drugs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 16.38 Crore | Market valuation of Beryl Drugs's shares. |
| Revenue (TTM) | 26.72 Crore | Total revenue generated by Beryl Drugs over the past twelve months. |
| Net Income (TTM) | +76.86 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +5.51% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +50.81% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+110.01% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.57 | Company's total debt divided by total shareholder equity. |
| Total Debt | 5.09 Crore | Sum of Beryl Drugs's current & long-term financial obligations. |
Is Beryl Drugs A Good Buy For Long Term?
Beryl Drugs, a small-cap stock with a market capitalization of ₹16.38 crore, shows mixed signals for long-term investment. While its impressive 3-year (316.13%) and 5-year (259.89%) returns are attractive, recent performance is less compelling (-6.41% in the past six months). The high profit margin (50.81%) and substantial revenue (₹26.72 crore in TTM) are positive, but the ₹5.09 crore debt reported in Q1 2024-25 warrants attention. Further investigation into the reasons for revenue fluctuation (110.01% change from the previous quarter) is needed. Considering the risks, it's an average buy for long-term investors with a high-risk tolerance.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
